F-STAR THERAPEUTICS, INC. Stock-Based Compensation
F-STAR THERAPEUTICS, INC. reported Stock-Based Compensation of $4.32 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2022-11-10
- F-STAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2022-09-30 was $1.45M, a 4.55% decline year-over-year.
- F-STAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2022-06-30 was $1.42M, a 23.83% decline year-over-year.
- F-STAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2022-03-31 was $1.45M, a 33.30% decline year-over-year.
- F-STAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2021-12-31 was $1.34M, a 4.19% increase year-over-year.
- F-STAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2021 was $6.90M, a 97.71% increase from fiscal 2020.
- F-STAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2020 was $3.49M, a 30.72% increase from fiscal 2019.
- F-STAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2019 was $2.67M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2022-09-30 | $1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.86M derived: sum of 2 quarters · filed 2022-11-10 | $4.32M 10-Q · filed 2022-11-10 | $5.66M derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | $1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.87M 10-Q · filed 2022-08-11 | $4.21M derived: sum of 3 quarters · filed 2022-08-11 | $5.73M derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-03-31 | $1.45M 10-Q · filed 2022-05-10 | $2.80M derived: sum of 2 quarters · filed 2022-05-10 | $4.31M derived: sum of 3 quarters · filed 2022-11-10 | $6.17M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $2.86M derived: sum of 2 quarters · filed 2022-11-10 | $4.72M derived: sum of 3 quarters · filed 2022-11-10 | $6.90M 10-K · filed 2022-03-15 |
| 2021-09-30 | $1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.37M derived: sum of 2 quarters · filed 2022-11-10 | $5.55M 10-Q · filed 2022-11-10 | $6.84M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $4.04M 10-Q · filed 2022-08-11 | $5.33M derived: sum of 3 quarters · filed 2022-08-11 | $6.52M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $2.18M 10-Q · filed 2022-05-10 | $3.47M derived: sum of 2 quarters · filed 2022-05-10 | $4.66M derived: sum of 3 quarters · filed 2022-05-10 | $5.13M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $2.48M derived: sum of 2 quarters · filed 2022-03-15 | $2.96M derived: sum of 3 quarters · filed 2022-03-15 | $3.49M 10-K · filed 2022-03-15 |
| 2020-09-30 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.67M derived: sum of 2 quarters · filed 2021-11-10 | $2.20M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $471.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $1.00M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $534.00K 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $2.67M 10-K · filed 2021-03-30 |